Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?

21.05.26 17:30 Uhr

Werte in diesem Artikel
Aktien

353,95 EUR -5,20 EUR -1,45%

Indizes

PKT PKT

29.118,2 PKT -322,1 PKT -1,09%

25.297,6 PKT -61,0 PKT -0,24%

7.354,0 PKT -3,5 PKT -0,05%

It has been about a month since the last earnings report for Intuitive Surgical, Inc. (ISRG). Shares have lost about 7.2% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Intuitive Surgical due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.ISRG Q1 Earnings & Sales Beat Estimates on Procedure GrowthIntuitive Surgical reported first-quarter 2026 adjusted earnings per share of $2.50, which beat the Zacks Consensus Estimate of $2.08 by 20.2%. The bottom line improved 38.1% year over year.GAAP earnings per share was $2.28 versus $1.92 a year ago.Revenue DetailsRevenues rose 23% from the year-ago quarter to $2.77 billion, which exceeded the Zacks Consensus Estimate by 6.2%. Growth reflected higher global procedure volume and stronger system placements, led by da Vinci 5.Segmental DetailsInstrument & Accessories: ISRG Procedure Growth Lifts High-Margin Recurring MixRevenues for this segment climbed 23.3% year over year to $1.69 billion, supported by procedure growth and customer buying patterns, alongside the sharp increase in Ion procedure volume.Worldwide procedures (da Vinci and Ion combined) increased about 17% versus the first quarter of 2025, with da Vinci procedures up roughly 16% and Ion procedures up about 39%. ISRG’s strong momentum during the quarter reflects broad-based adoption across its platforms, with strength in the United States and Europe and mixed results in parts of Asia.Systems: ISRG’s Placements Shift Further Toward da Vinci 5This segment’s revenues totaled $650.7 million, up 24.5% year over year, driven by capital strength. Intuitive Surgical placed 431 da Vinci systems in the quarter, up from 367 a year earlier. The mix continued to move toward the latest da Vinci 5, with 232 placements compared with 147 in the prior-year quarter. The company also placed 52 Ion systems, modestly higher than 49 a year ago, as Ion adoption expanded alongside growing procedure demand.Intuitive Surgical highlighted leasing as a meaningful part of placements, including usage-based arrangements, while trade-in activity rose as customers upgraded to da Vinci 5. The company ended the quarter with a da Vinci installed base of 11,395 systems, up 12% year over year, while Ion’s installed base rose 22% to 1,041 systems.ServicesRevenues from this segment improved 19% to $433.7 million, tracking the larger installed base and ongoing demand for support and maintenance.ISRG Margin Profile Improves Despite Tariff HeadwindsAdjusted gross profit was $1.88 billion, up 25.6% year over year. As a percentage of revenues, the gross margin was 67.8%, up approximately 140 bps from the prior-year quarter’s figure.Selling, general and administrative expenses totaled $613.3 million, up 8.9% year over year.Research and development expenses totaled $361.9 million, up 14.6% on a year-over-year basis.Adjusted operating income totaled $1.08 billion, up 40.3% year over year. As a percentage of revenues, the operating margin was 38.9%, up approximately 480 bps from the prior-year quarter’s figure.ISRG’s Financial PositionCapital allocation remained active during the quarter. ISRG repurchased 2.3 million shares for $1.1 billion, reducing cash, cash equivalents, and investments to $7.98 billion at quarter-end from $9.03 billion at the end of fiscal 2025.Management also pointed to continued investments in product and digital capabilities, including scaling da Vinci 5 globally and expanding the broader ecosystem that supports utilization and adoption.ISRG’s Procedure & Margin Outlook for 2026Following the quarter, Intuitive Surgical raised its full-year 2026 da Vinci procedure growth outlook to about 13.5-15.5%. The company also expects adjusted gross margin of 67.5% to 68.5% for 2026, a range that includes an estimated tariff impact of about 1% of revenues, and projects adjusted operating expense growth of 11-14%.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.VGM ScoresCurrently, Intuitive Surgical has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Intuitive Surgical has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Intuitive Surgical und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: Zacks

Nachrichten zu Intuitive Surgical Inc

Analysen zu Intuitive Surgical Inc

DatumRatingAnalyst
19.07.2019Intuitive Surgical BuyCanaccord Adams
22.04.2019Intuitive Surgical BuyCanaccord Adams
02.04.2019Intuitive Surgical BuyDeutsche Bank AG
19.10.2018Intuitive Surgical BuyCanaccord Adams
18.04.2018Intuitive Surgical BuyCanaccord Adams
DatumRatingAnalyst
19.07.2019Intuitive Surgical BuyCanaccord Adams
22.04.2019Intuitive Surgical BuyCanaccord Adams
02.04.2019Intuitive Surgical BuyDeutsche Bank AG
19.10.2018Intuitive Surgical BuyCanaccord Adams
18.04.2018Intuitive Surgical BuyCanaccord Adams
DatumRatingAnalyst
26.01.2018Intuitive Surgical HoldCanaccord Adams
18.07.2017Intuitive Surgical Sector PerformRBC Capital Markets
30.06.2017Intuitive Surgical NeutralCantor Fitzgerald
30.05.2017Intuitive Surgical HoldCanaccord Adams
17.04.2017Intuitive Surgical Sector PerformRBC Capital Markets
DatumRatingAnalyst
23.01.2015Intuitive Surgical SellCRT Capital
22.10.2014Intuitive Surgical SellCRT Capital
09.01.2009Intuitive Surgical DowngradeBrean Murray, Carret & Co., LLC
26.08.2005Update Intuitive Surgical Inc. : UnderperformJefferies & Co

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Intuitive Surgical Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen